Both higher HbA1C and presence of proliferative diabetic retinopathy are associated with poorer visual outcomes in eyes treated with intravitreal anti-VEGF for diabetic macula oedema [13,22]. The gene discussed is VEGFA; the disease is proliferative diabetic retinopathy.